Editorial

The Role of Urinary miRNAs in the Diagnosis, Management and Follow- Up of Prostatic Cancer

Author(s): Afroditi Ziogou, Alexios Giannakodimos and Ilias Giannakodimos*

Volume 12, Issue 2, 2023

Published on: 18 April, 2023

Page: [83 - 86] Pages: 4

DOI: 10.2174/2211536612666230324102850

Abstract

Diagnosis and management of prostatic cancer (PCa) cases mainly rely on levels of prostatic- specific antigen (PSA) levels. In the majority of cases, rising of PCa is usually responsible for elevated PSA. However, a wide variety of prostatic abnormalities, such as benign prostatic hyperplasia and infection or inflammation of the prostatic glands, may also impact prostate levels. Due to the low specificity and sensitivity of the PSA test, elevated PSA levels can lead to unnecessary prostate biopsies or surgical interventions, constituting this diagnostic modality a controversial screening test. Therefore, the discovery of new non-invasive biomarkers, such as urinary miRNAs, could shed light on the optimal management and follow-up of patients with prostatic lesions. This study aims to evaluate the utility of urinary miRNAs as a new PCa prognostic biomarker, discovering its current limitations and proposing methods to overwhelm current challenges.

Keywords: MiRNAs, prostate cancer, urine, urinary miRNA, prostatic-specific antigen, benign prostatic hyperplasia.

[1]
Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 2020; 77(1): 38-52.
[http://dx.doi.org/10.1016/j.eururo.2019.08.005] [PMID: 31493960]
[2]
Salido-Guadarrama AI, Morales-Montor JG, Rangel-Escareño C, et al. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone. Mol Med Rep 2016; 13(6): 4549-60.
[http://dx.doi.org/10.3892/mmr.2016.5095] [PMID: 27081843]
[3]
Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360(13): 1320-8.
[http://dx.doi.org/10.1056/NEJMoa0810084] [PMID: 19297566]
[4]
Dall’Era MA, Klotz L. Active surveillance for intermediate-risk prostate cancer. Prostate Cancer Prostatic Dis 2017; 20(1): 1-6.
[http://dx.doi.org/10.1038/pcan.2016.51] [PMID: 27801900]
[5]
Hasanoğlu S, Göncü B, Yücesan E, Atasoy S, Kayali Y, Özten Kandaş N. Investigating differential miRNA expression profiling using serum and urine specimens for detecting potential biomarkers for early prostate cancer diagnosis. Turk J Med Sci 2021; 51(4): 1764-74.
[http://dx.doi.org/10.3906/sag-2010-183] [PMID: 33550766]
[6]
Shin S, Park YH, Jung SH, et al. Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer. NPJ Genom Med 2021; 6(1): 45.
[http://dx.doi.org/10.1038/s41525-021-00212-w] [PMID: 34117264]
[7]
Venderbos LDF, Roobol MJ. PSA-based prostate cancer screening: The role of active surveillance and informed and shared decision making. Asian J Androl 2011; 13(2): 219-24.
[http://dx.doi.org/10.1038/aja.2010.180] [PMID: 21297655]
[8]
Roehrborn CG. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. Int J Impot Res 2008; 20(S3): S19-26.
[http://dx.doi.org/10.1038/ijir.2008.53] [PMID: 19002120]
[9]
Pan J, Ding M, Xu K, Yang C, Mao LJ. Exosomes in diagnosis and therapy of prostate cancer. Oncotarget 2017; 8(57): 97693-700.
[http://dx.doi.org/10.18632/oncotarget.18532] [PMID: 29228644]
[10]
Giannakodimos I. Urinary miRNAs as diagnostic biomarkers for prostatic cancer: Current dilemmas and novel potential role for digital rectal examination. Curr Med Chem 2022; 29(25): 4311-3.
[http://dx.doi.org/10.2174/0929867329666220118101733] [PMID: 35040397]
[11]
Akers JC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol 2013; 113(1): 1-11.
[http://dx.doi.org/10.1007/s11060-013-1084-8] [PMID: 23456661]
[12]
Otto JJ, Correll VL, Engstroem HA, et al. Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post‐DRE Urines for Quantitation and Genotype Determination. Proteomics Clin Appl 2020; 14(6): 2000012.
[http://dx.doi.org/10.1002/prca.202000012] [PMID: 32614141]
[13]
Paiva RM, Zauli DAG, Neto BS, Brum IS. Urinary microRNAs expression in prostate cancer diagnosis: A systematic review. Clin Transl Oncol 2020; 22(11): 2061-73.
[http://dx.doi.org/10.1007/s12094-020-02349-z] [PMID: 32323148]
[14]
Li Z, Li LX, Diao YJ, Wang J, Ye Y, Hao XK. Identification of Urinary Exosomal miRNAs for the Non-Invasive Diagnosis of Prostate Cancer. Cancer Manag Res 2021; 13: 25-35.
[http://dx.doi.org/10.2147/CMAR.S272140] [PMID: 33442291]
[15]
Wu D, Ni J, Beretov J, et al. Urinary biomarkers in prostate cancer detection and monitoring progression. Crit Rev Oncol Hematol 2017; 118: 15-26.
[http://dx.doi.org/10.1016/j.critrevonc.2017.08.002] [PMID: 28917266]
[16]
Foj L, Ferrer F, Serra M, et al. Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis. Prostate 2017; 77(6): 573-83.
[http://dx.doi.org/10.1002/pros.23295] [PMID: 27990656]
[17]
Kim MY, Shin H, Moon HW, Park YH, Park J, Lee JY. Urinary exosomal microRNA profiling in intermediate-risk prostate cancer. Sci Rep 2021; 11(1): 7355.
[http://dx.doi.org/10.1038/s41598-021-86785-z] [PMID: 33795765]
[18]
Kim J, Shim JS, Han BH, et al. Hydrogel-based hybridization chain reaction (HCR) for detection of urinary exosomal miRNAs as a diagnostic tool of prostate cancer. Biosens Bioelectron 2021; 192: 113504.
[http://dx.doi.org/10.1016/j.bios.2021.113504] [PMID: 34298498]
[19]
Mekhail SM, Yousef PG, Jackinsky SW, Pasic M, Yousef GM. miRNA in prostate cancer: new prospects for old challenges. EJIFCC 2014; 25(1): 79-98.
[PMID: 27683458]
[20]
Balacescu O, Petrut B, Tudoran O, et al. Urinary microRNAs for prostate cancer diagnosis, prognosis, and treatment response: Are we there yet? Wiley Interdiscip Rev RNA 2017; 8(6)
[http://dx.doi.org/10.1002/wrna.1438] [PMID: 28815924]
[21]
Etzioni R, Kooperberg C, Pepe M, Smith R, Gann PH. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics 2003; 4(4): 523-38.
[http://dx.doi.org/10.1093/biostatistics/4.4.523] [PMID: 14557109]
[22]
Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenges in using circulating miRNAs as cancer biomarkers. BioMed Res Int 2015; 2015: 1-10.
[http://dx.doi.org/10.1155/2015/731479] [PMID: 25874226]

© 2024 Bentham Science Publishers | Privacy Policy